Droxidopa Market, Global Outlook and Forecast 2023-2030
Droxidopa is a prodrug of norepinephrine used to increase the concentrations of these neurotransmitters in the body and brain. It is metabolized by aromatic L-amino acid decarboxylase (AAAD), also known as DOPA decarboxylase (DDC). Patients with NOH have depleted levels of norepinephrine which leads to decreased blood pressure or hypotension upon orthostatic challenge.[6] Droxidopa works by increasing the levels of norepinephrine in the peripheral nervous system (PNS), thus enabling the body to maintain blood flow upon and while standing. Droxidopa can also cross the blood?brain barrier (BBB) where it is converted to norepinephrine from within the brain. Increased levels of norepinephrine in the central nervous system (CNS) may be beneficial to patients in a wide range of indications. Droxidopa can be coupled with a peripheral aromatic L-amino acid decarboxylase inhibitor (AAADI) or DOPA decarboxylase inhibitor (DDC) such as carbidopa (Lodosyn) to increase central norepinephrine concentrations while minimizing increases of peripheral levels.
This report aims to provide a comprehensive presentation of the global market for Droxidopa, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Droxidopa. This report contains market size and forecasts of Droxidopa in global, including the following market information:
Global Droxidopa Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global Droxidopa Market Sales, 2018-2023, 2024-2030, (Ton)
Global top five Droxidopa companies in 2022 (%)
The global Droxidopa market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Purity?98% Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Droxidopa include Piramal Enterprises Limited, Lupin Ltd, Sun Pharmaceutical Industries Ltd., Clarochem Ireland, Estechpharma Co., Ltd., Chongqing Shenghuaxi Pharm Co.,Ltd. and JINLAN Pharm-Drugs Technology Co., Ltd., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Droxidopa manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Droxidopa Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (Ton)
Global Droxidopa Market Segment Percentages, by Type, 2022 (%)
Purity?98%
Purity<98%
Global Droxidopa Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (Ton)
Global Droxidopa Market Segment Percentages, by Application, 2022 (%)
Droxidopa Tablets
Droxidopa Capsules
Others
Global Droxidopa Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (Ton)
Global Droxidopa Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Droxidopa revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Droxidopa revenues share in global market, 2022 (%)
Key companies Droxidopa sales in global market, 2018-2023 (Estimated), (Ton)
Key companies Droxidopa sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Piramal Enterprises Limited
Lupin Ltd
Sun Pharmaceutical Industries Ltd.
Clarochem Ireland
Estechpharma Co., Ltd.
Chongqing Shenghuaxi Pharm Co.,Ltd.
JINLAN Pharm-Drugs Technology Co., Ltd.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Droxidopa, market overview.
Chapter 2: Global Droxidopa market size in revenue and volume.
Chapter 3: Detailed analysis of Droxidopa manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Droxidopa in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Droxidopa capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
